Continuous Cardiac Monitoring: Redefining the “End” of a Clinical Study?

Therapeutic drug monitoring (TDM) is vital for patient safety and regulatory approval, but traditionally it relies on a “snapshot” approach that increases the risk of missing important symptoms. According to one study, the clinician-recommended monitoring interval for most drugs is either three or six months and is often limited to a single blood draw.

Continuous monitoring through wearable devices can solve this problem by providing a constant stream of patient data, increasing the chances of catching escalations early, granting developers insight into how patients function in the real world, and tightening safety protocols to expedite approvals.

Two recent studies using wearable cardiac monitors demonstrate how this technology is capable of blurring the line between clinical trials and postmarket clinical care. The results of this shift are better patient care and a faster, less expensive drug development cycle thanks to lower site costs and wearable device reusability.

Early Detection in Post-Cardiac Surgery 

In one study at Brigham and Women’s Hospital in Boston, researchers found that continuous cardiac rhythm monitoring for up to 14 days after cardiac surgery post-discharge helped uncover cases of postoperative atrial fibrillation (poAF) that may have otherwise gone undetected. Atrial fibrillation (AFib) is the most common complication of cardiac surgery, affecting up to 40-50% of patients. This irregular heart rhythm can significantly increase the chance of blood clots in the heart and thus the risk of stroke. It also weakens the heart muscle by eliminating the “atrial kick.” The chronic inefficiency in pumping and filling eventually increases the risk of heart failure.

What makes AFib difficult to monitor is that it can be symptomatic or asymptomatic. Some people notice palpitations, shortness of breath and light-headedness, while others notice nothing. While the condition itself isn’t life-threatening, it requires treatment in order to prevent escalation.

In the study, 24% of patients who developed AFib saw their symptoms detected first through the wearable monitor after discharge, not during hospitalization. In 80% of these cases, the arrhythmia was not diagnosed using standard techniques until the three-month follow-up appointment.

For trial sponsors and drug developers, this study shows just how quickly adverse effects can begin and how continuous monitoring has the potential to help mitigate complications, providing opportunities for prompt intervention and dosage adjustment.

Cross-System Signaling in Epilepsy

Continuous cardiac monitoring isn’t helpful only for cardiology studies; because heart health is connected to many therapeutic areas, continuous monitoring both safeguards the heart and provides early warnings of complications in other systems that affect cardiac activity.

For example, early findings from an ongoing hospital-based study at Ochsner Health in New Orleans suggest that seizures may disrupt the coordination of the heart’s upper and lower chambers, potentially causing arrhythmias resulting in reduced oxygen flow to the brain and other organs. In epilepsy patients, seizures can also compromise heart and lung operation, causing apnea and/or a dangerous heart rhythm, leading to sudden unexpected death in epilepsy (SUDEP).

While the study’s goal is to understand the connections between epilepsy seizures and the heart, it provides a key example of how the body’s systems are interconnected and how cardiac monitoring can play a crucial role in clinical testing and postmarket TDM. This is especially true for cardiovascular and neurological drugs that have a high risk of side effects or toxicity.

Continuous Oversight as a Strategic Edge

Continuous monitoring through wearables offers three main advantages that have the potential to define success for the industry in coming years. The most obvious is in the regulatory process, where long-term, high-fidelity data can be used to satisfy from premarket to postmarket safety study requirements.

Historically, when a Phase III trial ends and a drug is approved, developers lose access to high-volume data about their product. This is no longer the case with wearables, potentially leading to faster approvals for label expansions and allowing companies to prove the safety and efficacy of their products across unfiltered patient populations.

Increased safety also provides a second advantage: reduced liability and lower risk of hospitalizations from complications. As the Brigham and Women’s Hospital study showed, a follow-up or TDM appointment every few months is not often enough to catch intermittent symptoms of larger problems, especially when the signs, like arrhythmias, need prompt treatment to prevent escalation. Early interventions manage the condition at a less severe stage and reduce the likelihood of it exacerbating into a more severe stage.

The third advantage is operational — wearables have the potential to drastically reduce trial overhead because they cut down the need for physical study sites. With automatic data capture through the device, there’s no need for manual data entry. Additionally, many wearable devices are reusable, allowing them to be deployed for different studies and cutting costs further.

The New Standard of Care

The distinction between being a participant in a study and a patient in care is fading quickly with new advancements in technology, automated workflow, and data scrutiny. Continuous monitoring marks a fundamental change in the pharmaceutical landscape, one where companies are no longer just selling a product but providing a protected outcome. Being able to detect life-threatening side effects or sudden cardiac risks in real-time is no longer just a technical upgrade; it’s a new standard of care that will define industry success.

Historically, real-world care has been unpredictable and distinct from the controlled environment of the study, but no longer. Companies that lead the next decade will be those who embrace this change, replacing episodic data with continuous streams, reducing overhead, satisfying regulatory safety requirements with unprecedented speed, and providing a safety net for trial participants long after they’ve become patients.

The post Continuous Cardiac Monitoring: Redefining the “End” of a Clinical Study? appeared first on MedTech Intelligence.

🔗 Read the full article on the original source